INILAH ceritanya PASAI DARA.
DARA BioSciences Inc. (DARA) released further positive results from a mid-stage study of its experimental drug to treat neuropathic pain caused by chemotherapy.
Shares jumped 10% to $2.39 as the company also said it has expanded its patent portfolio by 11 U.S. and foreign patents over the past 12 months.
The study showed the drug, dubbed KRN5500, reduced allodynia, an abnormal pain response to normally non-painful stimuli such as a light touch or change in temperature, DARA said Tuesday. DARA had already released data showing the treatment met its primary endpoints.
The company acquires drug candidates from third parties seeking to advance their development and later sell or license them to larger drug makers. It has been unprofitable as it generates no revenue.
No comments:
Post a Comment